News | July 13, 2022
Eversana partners with Compai Pharma to expand commercialisation services across APAC
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
_256_384.png)
Researchers from Bar-Ilan University find that even in old age, feeling young can lower the risks of developing physical disability and morbidity
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Site Enhances New Modality CRDMO Platform Capacity for Customers
Medicfibers in collaboration with AIIMS New Delhi, has developed an antimicrobial solution Viroclog that when applied as a coating on textiles, provides long-lasting protection against HAI by reducing virus, bacteria, fungi survival on fabric
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Subscribe To Our Newsletter & Stay Updated
